Literature DB >> 19414076

More rare birds, and the occasional swan.

Brian R Edlin, Marla A Shu, Emily Winkelstein, Don C Des Jarlais, Michael P Busch, Barbara Rehermann, Thomas R O'Brien, Andrew H Talal, Leslie H Tobler, Marija Zeremski, Ann B Beeder.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19414076      PMCID： PMC3690554          DOI： 10.1053/j.gastro.2009.04.040

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  10 in total

1.  Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?

Authors:  B R Edlin; K H Seal; J Lorvick; A H Kral; D H Ciccarone; L D Moore; B Lo
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

2.  Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis.

Authors:  A H Kral; R N Bluthenthal; J Lorvick; L Gee; P Bacchetti; B R Edlin
Journal:  Lancet       Date:  2001-05-05       Impact factor: 79.321

3.  Managing Hepatitis C in Users of Illicit Drugs.

Authors:  Brian R Edlin; Michael R Carden; Stephen J Ferrando
Journal:  Curr Hepat Rep       Date:  2007

4.  Rare birds in North America: acute hepatitis C cohorts.

Authors:  Andrea L Cox; Kimberly Page; Julie Bruneau; Naglaa H Shoukry; Georg M Lauer; Arthur Y Kim; Hugo R Rosen; Hank Radziewicz; Arash Grakoui; Daniel S Fierer; Andrea D Branch; David E Kaplan; Kyong-Mi Chang
Journal:  Gastroenterology       Date:  2008-12-04       Impact factor: 22.682

5.  Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates.

Authors:  Kimberly Page-Shafer; Brandee L Pappalardo; Leslie H Tobler; Bruce H Phelps; Brian R Edlin; Andrew R Moss; Teresa L Wright; David J Wright; Thomas R O'Brien; Sally Caglioti; Michael P Busch
Journal:  J Clin Microbiol       Date:  2007-11-21       Impact factor: 5.948

6.  Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV.

Authors:  Eishiro Mizukoshi; Christoph Eisenbach; Brian R Edlin; Kimberly P Newton; Sukanya Raghuraman; Christina Weiler-Normann; Leslie H Tobler; Michael P Busch; Mary Carrington; Jane A McKeating; Thomas R O'Brien; Barbara Rehermann
Journal:  J Infect Dis       Date:  2008-07-15       Impact factor: 5.226

7.  The inverse relationship between chronic HBV and HCV infections among injection drug users is associated with decades of age and drug use.

Authors:  F-C Tseng; B R Edlin; M Zhang; A Kral; M P Busch; B A Ortiz-Conde; T M Welzel; T R O'Brien
Journal:  J Viral Hepat       Date:  2008-05-27       Impact factor: 3.728

8.  Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000.

Authors:  Fan-Chen Tseng; Thomas R O'Brien; Mingdong Zhang; Alex H Kral; Betty A Ortiz-Conde; Jennifer Lorvick; Michael P Busch; Brian R Edlin
Journal:  Hepatology       Date:  2007-09       Impact factor: 17.425

9.  Syringe and needle exchange as HIV/AIDS prevention for injection drug users.

Authors:  J K Watters; M J Estilo; G L Clark; J Lorvick
Journal:  JAMA       Date:  1994-01-12       Impact factor: 56.272

10.  Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users.

Authors:  M Zeremski; M A Shu; Q Brown; Y Wu; D C Des Jarlais; M P Busch; A H Talal; B R Edlin
Journal:  J Viral Hepat       Date:  2008-07-17       Impact factor: 3.728
  10 in total
  12 in total

1.  Genotype imputation performance of three reference panels using African ancestry individuals.

Authors:  Candelaria Vergara; Margaret M Parker; Liliana Franco; Michael H Cho; Ana V Valencia-Duarte; Terri H Beaty; Priya Duggal
Journal:  Hum Genet       Date:  2018-04-10       Impact factor: 4.132

2.  Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion.

Authors:  Sukanya Raghuraman; Heiyoung Park; William O Osburn; Emily Winkelstein; Brian R Edlin; Barbara Rehermann
Journal:  J Infect Dis       Date:  2012-01-31       Impact factor: 5.226

3.  Active opioid use does not attenuate the humoral responses to inactivated influenza vaccine.

Authors:  Ekaterina Moroz; Randy A Albrecht; Brandon Aden; Ann Bordwine Beeder; Jianda Yuan; Adolfo García-Sastre; Brian R Edlin; Mirella Salvatore
Journal:  Vaccine       Date:  2016-02-06       Impact factor: 3.641

4.  Trans-ancestral fine-mapping of MHC reveals key amino acids associated with spontaneous clearance of hepatitis C in HLA-DQβ1.

Authors:  Ana Valencia; Candelaria Vergara; Chloe L Thio; Nicolas Vince; Venceslas Douillard; Alba Grifoni; Andrea L Cox; Eric O Johnson; Alex H Kral; James J Goedert; Alessandra Mangia; Valeria Piazzolla; Shruti H Mehta; Gregory D Kirk; Arthur Y Kim; Georg M Lauer; Raymond T Chung; Jennifer C Price; Salim I Khakoo; Laurent Alric; Matthew E Cramp; Sharyne M Donfield; Brian R Edlin; Michael P Busch; Graeme Alexander; Hugo R Rosen; Edward L Murphy; Genevieve L Wojcik; Mary Carrington; Pierre-Antoine Gourraud; Alessandro Sette; David L Thomas; Priya Duggal
Journal:  Am J Hum Genet       Date:  2022-01-31       Impact factor: 11.043

5.  Ethical and Practical Issues Associated With the Possibility of Using Controlled Human Infection Trials in Developing a Hepatitis C Virus Vaccine.

Authors:  Andrea Cox; Mark Sulkowski; Jeremy Sugarman
Journal:  Clin Infect Dis       Date:  2020-12-31       Impact factor: 20.999

6.  Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: Implications for prevention.

Authors:  Benjamin Eckhardt; Emily R Winkelstein; Marla A Shu; Michael R Carden; Courtney McKnight; Don C Des Jarlais; Marshall J Glesby; Kristen Marks; Brian R Edlin
Journal:  PLoS One       Date:  2017-05-19       Impact factor: 3.240

Review 7.  Approaches, Progress, and Challenges to Hepatitis C Vaccine Development.

Authors:  Justin R Bailey; Eleanor Barnes; Andrea L Cox
Journal:  Gastroenterology       Date:  2018-09-27       Impact factor: 22.682

8.  Per-Contact Infectivity of Hepatitis C Virus Acquisition in Association With Receptive Needle Sharing Exposures in a Prospective Cohort of Young Adult People who Inject Drugs in San Francisco, California.

Authors:  Yuridia Leyva; Kimberly Page; Stephen Shiboski; Judith A Hahn; Jennifer Evans; Erik Erhardt
Journal:  Open Forum Infect Dis       Date:  2020-03-16       Impact factor: 3.835

9.  Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts.

Authors:  Priya Duggal; Chloe L Thio; Genevieve L Wojcik; James J Goedert; Alessandra Mangia; Rachel Latanich; Arthur Y Kim; Georg M Lauer; Raymond T Chung; Marion G Peters; Gregory D Kirk; Shruti H Mehta; Andrea L Cox; Salim I Khakoo; Laurent Alric; Matthew E Cramp; Sharyne M Donfield; Brian R Edlin; Leslie H Tobler; Michael P Busch; Graeme Alexander; Hugo R Rosen; Xiaojiang Gao; Mohamed Abdel-Hamid; Richard Apps; Mary Carrington; David L Thomas
Journal:  Ann Intern Med       Date:  2013-02-19       Impact factor: 25.391

Review 10.  Challenges and Promise of a Hepatitis C Virus Vaccine.

Authors:  Andrea L Cox
Journal:  Cold Spring Harb Perspect Med       Date:  2020-02-03       Impact factor: 6.915
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.